

2022-2023: Accomplishments

Publications:

1. Brancazio SN, Lehman A, Kemp EV, Brown J, Crane EK, Tait DL, Taylor VD, Naumann RW. Factors Associated with Same Day Discharge after Laparoscopic Surgery in Gynecologic Oncology. *J Minim Invasive Gynecol*. 2022 Jan;29(1):114-118. doi: 10.1016/j.jmig.2021.06.026. Epub 2021 Jul 22. PMID: 34224874.
2. Lees B, Brown J. Evaluation and Management of Common Intraoperative and Postoperative Complications in Gynecologic Endoscopy. *Obstet Gynecol Clin North Am*. 2022 Jun;49(2):355-368. doi: 10.1016/j.ogc.2022.03.002. PMID: 35636813.
3. Crane E. Beyond Serous: Treatment Options for Rare Endometrial Cancers. *Curr Treat Options Oncol*. 2022 Nov;23(11):1590-1600. doi: 10.1007/s11864-022-01014-7. Epub 2022 Oct 7. PMID: 36205807.
4. Levytska K, Yu Z, Wally M, Odum S, Hsu JR, Seymour R, Brown J, Crane EK, Tait DL, Puechl AM, Lees B, Naumann RW. Enhanced recovery after surgery (ERAS) protocol is associated with lower post-operative opioid use and a reduced office burden after minimally invasive surgery. *Gynecol Oncol*. 2022 Jul 4:S0090-8258(22)00424-3. doi: 10.1016/j.ygyno.2022.06.020. Epub ahead of print. PMID: 35798598.
5. Lovell DY, Naumann RW. The Benefits of Laparoscopic Radical Hysterectomy for Cervical Cancer: Res Ipsa Loquitur? *J Minim Invasive Gynecol*. 2022 Jul;29(7):805-806. doi: 10.1016/j.jmig.2022.05.011. Epub 2022 May 19. PMID: 35598873.
6. Lees BF, Johnson S, Donahue E, Bose R, Brown J, Crane E, Puechl A, Tait D, Naumann RW. Improved Rates of Same-day Discharge in Patients Undergoing Surgery for Endometrial Cancer Following the COVID-19 Pandemic. *J Minim Invasive Gynecol*. 2022 Nov;29(11):1248-1252. doi: 10.1016/j.jmig.2022.07.013. Epub 2022 Aug 5. PMID: 35940525; PMCID: PMC9354383.
7. Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, Brown J. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. *Int J Gynecol Cancer*. 2022 Aug 16;32(10):1250–7. doi: 10.1136/ijgc-2022-003492. Epub ahead of print. PMID: 35973737; PMCID: PMC9554028.
8. Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath Iii C, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777. PMID: 35064011; PMCID: PMC8785197.
9. Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssofian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol*. 2022 Apr 19;JCO2101801. doi: 10.1200/JCO.21.01801. Epub ahead of print. PMID: 35439029.

10. Farhangfar CJ, Scarola GT, Morris VA, Farhangfar F, Dumas K, Symanowski J, Hwang JJ, Mileham KF, Carrizosa DR, Naumann RW, Livasy C, Kim ES, Raghavan D. Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients. *JCO Clin Cancer Inform.* 2022 Jul;6:e2200011. doi: 10.1200/CCI.22.00011. PMID: 35839431.
11. Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Molecular profiles of endometrial cancer tumors among Black patients. *Gynecol Oncol.* 2022 Jul;166(1):108-116. doi: 10.1016/j.ygyno.2022.04.014. Epub 2022 Apr 28. PMID: 35490034.
12. Klc TR, Wu S, Wilhite AM, Jones NL, Powell MA, Olawaiye A, Girda E, Brown J, Puechl A, Ali-Fehmi R, Winer IS, Herzog TJ, Korn WM, Erickson BK. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. *Gynecol Oncol.* 2022 Sep 13:S0090-8258(22)00592-3. doi: 10.1016/j.ygyno.2022.09.006. Epub ahead of print. PMID: 36114027.
13. Ackroyd SA, Arguello D, Ramos P, Mahdi H, ElNaggar A, Winer I, Holloway R, Krivak T, Jones N, Turner VG, Herzog T, Chu C, Brown J, Mantia-Smaldone G. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. *Gynecol Oncol.* 2022 Nov 1:S0090-8258(22)01897-2. doi: 10.1016/j.ygyno.2022.10.020. Epub ahead of print. PMID: 36333181.
14. ElNaggar A, Robins D, Baca Y, Arguello D, Ulm M, Arend R, Mantia-Smaldone G, Chu C, Winer I, Holloway R, Krivak T, Jones N, Galvan-Turner V, Herzog TJ, Brown J. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. *Gynecol Oncol.* 2022 Oct 10:S0090-8258(22)01850-9. doi: 10.1016/j.ygyno.2022.09.022. Epub ahead of print. PMID: 36229265.
15. Leitao MM Jr, Zhou QC, Brandt B, Iasonos A, Sioulas V, Lavigne Mager K, Shahin M, Bruce S, Black DR, Kay CG, Gandhi M, Qayyum M, Scalici J, Jones NL, Paladugu R, Brown J, Naumann RW, Levine MD, Mendivil A, Lim PC, Kang E, Cantrell LA, Sullivan MW, Martino MA, Kratz MK, Kolev V, Tomita S, Leath CA 3rd, Boitano TKL, Doo DW, Feltmate C, Sugrue R, Olawaiye AB, Goldfeld E, Ferguson SE, Suhner J, Abu-Rustum NR. The MEMORY Study: Multicenter study of Minimally invasive surgery versus Open Radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. *Gynecol Oncol.* 2022 Sep;166(3):417-424. doi: 10.1016/j.ygyno.2022.07.002. Epub 2022 Jul 22. PMID: 35879128.
16. Zanolli NC, Gatta LA, Fish L, Falkovic M, Lorenzo A, Puechl AM, Havrilesky LJ, Davidson B. A Qualitative Assessment of Patient Experience following Systematic Implementation of Goals of Care Conversations in the Ambulatory Gynecologic Oncology Setting. *Palliat Med Rep.* 2022 Nov 22;3(1):308-315. doi: 10.1089/pmr.2022.0040. PMID: 36479549; PMCID: PMC9712054.
17. Davidson BA, Puechl AM, Watson CH, Lim S, Gatta L, Monuszko K, Drury K, Ryan ES, Rice S, Truong T, Ma J, Power S, Jordan W, Kurtovic K, Havrilesky LJ. Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers. *Gynecol Oncol.* 2022 Feb;164(2):288-294. doi: 10.1016/j.ygyno.2021.12.009. Epub 2021 Dec 16. PMID: 34922770; PMCID: PMC8799508.
18. Rush SK, Lees BF, Huang DS, Peterson MF, Al-Niaimi A. Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of

- outcomes. *Gynecol Oncol*. 2022 Sep 13;S0090-8258(22)00577-7. doi: 10.1016/j.ygyno.2022.08.023. Epub ahead of print. PMID: 36114028.
19. Penick ER, Bateman NW, Rojas C, Magana C, Conrads K, Zhou M, Hood BL, Wang G, Parikh N, Huang Y, Darcy KM, Casablanca Y, Mhawech-Fauceglia P, Conrads TP, Maxwell GL. Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues. *Clin Proteomics*. 2022 Oct 4;19(1):35. doi: 10.1186/s12014-022-09372-y. PMID: 36195845; PMCID: PMC9531351.
 20. Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, Herzog T, Kapp DS, Monk BJ, Casablanca Y, Hanjani P, Wenham RM, Walker J, McNally L, Copeland LJ, Robertson S, Lentz S, Spirtos NM, Bell JG. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. *Gynecol Oncol*. 2022 Dec;167(3):429-435. doi: 10.1016/j.ygyno.2022.09.028. Epub 2022 Oct 14. PMID: 36244828.
 21. Delara R, Islam M, Thomas N, Mi L, Lim E, Yi J. Shared decision-making in opioid prescribing for minimally invasive hysterectomy: A prospective randomized controlled trial. *J Opioid Manag*. 2022 Sep-Oct;18(5):475-485. doi: 10.5055/jom.2022.0741. PMID: 36226787.
 22. Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCs Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. *Cancer*. 2022 Dec 26. doi: 10.1002/cncr.34582. Epub ahead of print. PMID: 36572991.
 23. Jones W, Tait D, Livasy C, Ganapathy M, Ganapathi R. PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer. *NAR Cancer*. 2022; 4(3):1-12. Doi:10.1093/Narcan/zcac026.

Presentations:

1. Evan Schrader, Plenary Speaker: Race matters: Disparities in the use of maintenance therapy in ovarian cancer, SGO 2022
2. Khrystyna Levytska, Poster Presenter: Enhanced recovery after surgery protocol is associated with lower post-operative opioid use and a reduced post-operative office burden, SGO 2022
3. Danny Lovell, Poster Presenter, Minimally invasive surgery for recurrent ovarian cancer: Big gains from small incisions. South Atlantic Association of Obstetricians and Gynecologists annual meeting, 2022.
4. Erin Crane: Surgical Educator for Advanced Surgical Debulking Master Class, SGO 2022.
5. Jubilee Brown: Rare but Revelatory Master Class lecture, Rare Tumor Debate; Chair and Moderator, Opening Plenary Session, "Breaking Barriers," SGO 2022.
6. Allison Puechl: "She dunks on cancer" Webinar for the Endometrial Cancer Molecularly Targeted Therapy Consortium, 2022.
7. Allison Puechl: International Gynecologic Cancer Society Kazakhstan Tumor Board featured speaker, January 2022.
8. Allison Puechl: Progestin therapy in endometrial cancer, Society of Gynecologic Oncology Winter Meeting, January 2022 (delivered in absentia).
9. Wilhite AM, Wu S, Zeng J, Magee D, In G, Herzog TJ, Wallbillich JJ, Gibney G, Phung T, Brown J, et al. Investigating molecular profiles of subtypes of mucosal melanomas: Is vulvovaginal melanoma a distinct entity? Poster Presentation (Wilhite AM, presenter). Society of Gynecologic Oncology Winter Meeting, January 2022. Abstract in press.
10. Wilhite, AM, Wu S, Zeng J, Magee D, In G, Herzog TJ, Wallbillich JJ, Gibney G, Phung T, Brown J, et al. Vulvovaginal melanoma or vulvar and vaginal melanoma: Can these tumors be considered the same? Oral presentation (Wilhite AM, presenter). Society of Gynecologic Oncology Annual Meeting, March 2022. In press.
11. Jubilee Brown: Malignancy risk in fibroids: When Gyn Onc and MIS Collide. CanSAGE Webinar (Canadian Society for Advancing Gynecologic Excellence), Plenary discussion (virtual), April 2022
12. Jubilee Brown: Role of Minimally Invasive Surgery Cytoreduction in Ovary Cancer. Society of Gynecologic Oncology Winter Meeting, January 2022.
13. Jubilee Brown: Florida Society of Gynecologic Oncology Annual Meeting; Minimally Invasive Surgery in Ovarian Cancer, June 2022.
14. Wendel Naumann: Florida Society of Gynecologic Oncology Annual Meeting; ASCO Update, June 2022
15. Erin Crane: group leader for "Turning Complexity into Clarity in Advanced Cervical Cancer" (SGO-sponsored CME program focused on cervical cancer)
16. Erin Crane: Course Director, Best of ASCO lecture at the Ballantyne, Charlotte, NC, June 2022
17. Erin Crane – OncLive, on gynecologic oncology fellowship
<https://atriumhealth.org/education/graduate-medical-education/physician-fellowships/gynecologic-oncology>
18. Lovell DY, Levytska K, Brown J, Instructional video on Tandem Cuff Closure. Video Presentation at AAGL Global Congress, Aurora CO, December 2022.

19. Chen J, Brown J, Crane E, Lees B, Puechl A, Naumann RW. Minimally invasive technique not associated with worse prognosis in patients with stage I uterine papillary serous carcinoma (UPSC). Oral presentation, AAGL Global Congress, Aurora CO, December 2022.
20. Khalighi PR, Tam J, Delara RM. Two approaches to laparoscopic removal of Essure coils: Salpingectomy and cornuectomy. AAGL Global Congress, Aurora CO, December 2022.
21. Delara R, McHale C, Pal D, Maddeboina K, Naumann RW, Crane E, Brown J, Durden D. Treating endometrial adenocarcinoma using. Multitarget PI3K/BRD4/CDK4/6/9 small molecule inhibitors. Oral presentation, Mid-Atlantic Gynecologic Oncology Society Meeting, Nashville TN, November 2022
22. Levytska K, Naumann RW, Benfield MJ, Crane EK. Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies. Poster presentation, International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
23. Holloway R with Crane EK et al. Phase 3 study of efficacy and safety of Olvi-vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (Onprime; GOG-3076) [NCT05281471], Poster presentation, International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
24. Muggio D, Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J et al. Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study. Poster presentation, International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
25. Naumann RW. Case Presentations, moderator. International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
26. Tinker A, with Brown J et al. Post-hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
27. Brown J. The Utility of Molecular Profiling in Rare Gynecologic Cancers, Educational Symposium, International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
28. Brown J. Management of urinary complications. International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
29. Brown J. Distillation, Leiomyosarcoma and morcellation. International Gynecologic Cancer Society Annual Congress, New York NY, October 2022.
30. Brown J. Low grade serous ovarian cancer Consensus Conference and educational video presentation, New York NY, October 2022.
31. Brown J. Progress in Rare Ovarian Tumors. Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston TX, October 2022.
32. Naumann RW. Project ECHO Kazakhstan Tumor Board (monthly), Chair, International Gynecologic Cancer Society, October-December 2022.
33. Brown J. Round Table Luncheon – Removing large masses from small openings, AAGL Global Congress, Aurora CO, December 2022.
34. Naumann RW. Oral presentation, Cervical Cancer, Opinions in Gynecologic Malignancies, New Orleans LA, November 2022.

35. Brown J. Opinions in Ovarian Cancer. Virtual presentation, South Carolina and North Carolina, October 2022.

Grants/Awards:

1. Allison Puechl: APGO/CREOG Resident Teaching Award
2. Allison Puechl: Travel Scholarship to NRG Oncology as New Investigator Award (funding through July 2025)
3. Allison Puechl: APGO/CREOG Surgical Scholar
4. Allison Puechl: SGO Bridges Award
5. Wendel Naumann – R-01 RESPITE Grant Co-Investigator in collaboration with Wake Forest University: REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE) trial (2% Effort)
6. Wendel Naumann: Travel Scholarship to GOG Partners as Business development liaison
7. Wendel Naumann: SGO Program Committee 2023
8. Wendel Naumann: Charlotte Top Doctor Award
9. Danny Lovell – Deal Fund Travel Award for Video at AAGL (J. Brown, Mentor)
10. Khrystyna Levytska – Deal Fund Travel Award for IGCS presentation (E. Crane, Mentor)
11. Brittany Lees – R-01 RESPITE Grant Co-Principal Investigator in collaboration with Wake Forest University: REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE) trial (10% Effort)
12. Sasha Davenport: invited to submit full CTSI Pilot grant application (J. Brown, Mentor)
13. Erin Crane – Travel Scholarship to NRG Oncology as GOG Scholar
14. Erin Crane: Recognized as an outstanding editorial board reviewer for Gynecologic Oncology Reports
15. Erin Crane: Charlotte Top Doctor Award
16. Jane Chen – Deal Fund Travel Award for AAGL presentation (RW Naumann, Mentor)
17. Jo Casablanca – APGO/CREOG Surgical Scholar
18. Jubilee Brown - Grant from the NRG Oncology as Co-Chair of Rare Tumor Group
19. Jubilee Brown: Charlotte Top Doctor Award

Current Clinical Trial National Leadership/Steering Committees:

RW Naumann: STRO-002 GM-1, GM-2, and GM-3; Navicizumab; BMS-352 (closed and in press); DSMB for ROCC and On-Prime studies
Brown J: BOUQUET, GARNET, GOG 264 (closed and manuscript in process)

Steering Committee/Advisory Boards:

Dr. Brown: NRG 3051 (BOUQUET Rare Tumor Trial, International Steering Committee)
Dr. Crane: Committee member: High Risk for Breast Cancer Assessment and Care Program
Dr. Naumann: Stro-001 and Stro-002 (International PI), OncZerna-301 (navacizumab trial); GOG-3028; RaPIDS trial; DSMB GOG-3074

National Committee/Leadership Activity:

1. Erin Crane: NRG Oncology Developmental Therapeutics Committee

2. Erin Crane: SGO Clinical Practice Committee
3. Brittany Lees: SGO Policy, Quality, and Outcomes Subcommittee
4. Allison Puechl: NRG Oncology Uterine Corpus Committee
5. Wendel Naumann: SGO Nominating Committee
6. Wendel Naumann: SGO Winter meeting Program Co-Chair
7. Wendel Naumann: IGCS Kazakhstan Tumor Board Lead
8. Wendel Naumann: IGCS 360 Education Committee Chair
9. Jubilee Brown: SGO Board of Directors
10. Jubilee Brown: 2022 SGO Steering Committee
11. Jubilee Brown: SGO Board Liaison for Ethics Committee and Winter Meeting
12. Jubilee Brown: IGCS 2022 Program Committee

Education:

Fellowship:

- ACGME Approval
- Dr. Erin Crane: Fellowship Program Director
- Dr. Jo Casablanca: Fellowship Associate Program Director
- Dr. Ritchie Delara - inaugural fellow
- Successful match of Dr. Mujumdar

Residency:

Dr. Allison Puechl: Residency Clerkship Director, Gynecologic Oncology

Promotion:

Dr. Erin Crane promoted to Clinical Associate Professor at Wake Forest University

Faculty Recruitment:

Dr. Yovanni Casablanca joined the faculty

Administrative Service:

Jubilee Brown: Appointed to the Atrium Health / Wake Forest School of Medicine Promotions and Tenure Committee; Atrium Health Cancer Center President Search Committee

Notable Mentions in the Press:

-
Dr. Naumann: Channel 3 WBTV feature on cervical cancer
<https://www.wbvtv.com/2022/01/20/its-not-really-something-that-kind-crosses-your-mind-woman-recalls-shock-cervical-cancer-diagnosis-30/>

Erin Crane: TV interview: Professional Television Network and its program, Healthcasts, which is a leading educational resource for over 130,000 US physicians that spans 30 clinical specialty areas. Through member feedback, Healthcasts delivers highlights from more than 50 medical

conferences, research insights from Key Opinion Leaders, FDA /CDER, CDC, NIH interviews and CME programming through partnerships with leading educational institutions. Healthcast's medical content is available on-demand across all digital platforms.

Jubilee Brown: Clinical Care Options Podcast, 2022 Global Conference Coverage: An Update on the Clinical Developments Across Gynecologic Malignancies

2023

Publications

1. Levytska K, Pena SR, Brown J, Yu Z, Wally MK, Hsu JR, Seymour RB, Naumann W; PRIMUM Group. Opioid and benzodiazepine use in gynecologic oncology patients. *Int J Gynecol Cancer*. 2023 Feb 21;ijgc-2022-003955. doi: 10.1136/ijgc-2022-003955. Epub ahead of print. PMID: 36810232.
2. Ackroyd SA, Arguello D, Ramos P, Mahdi H, ElNaggar A, Winer I, Holloway R, Krivak T, Jones N, Turner VG, Herzog T, Chu C, Brown J, Mantia-Smaldone G. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. *Gynecol Oncol*. 2023 Feb;169:164-171. doi: 10.1016/j.ygyno.2022.10.020. Epub 2022 Nov 1. PMID: 36333181.
3. Kucera CW, Tian C, Tarney CM, Presti C, Jokajty S, Winkler SS, Casablanca Y, Bateman NW, Mhaweche-Fauceglia P, Wenzel L, Hamilton CA, Chan JK, Jones NL, Rocconi RP, O'Connor TD, Farley JH, Shriver CD, Conrads TP, Phippen NT, Maxwell GL, Darcy KM. Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. *JAMA Netw Open*. 2023 Apr 3;6(4):e238437. doi: 10.1001/jamanetworkopen.2023.8437. PMID: 37067801; PMCID: PMC10111180.
4. Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, McCoy A, Houston N, Lee JM, Lipkowitz S, Zimmer A, Pavelova M, Villanueva EN, Smith L, Blakely A, Casablanca Y, Highfill SL, Stroncek DF, Collins-Johnson N, Panch S, Procter J, Pham C, Korrapati S, Holland SM, Rosen LB, Nunes AT, Zoon KC, Cole CB, Annunziata CM. Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. *Clin Cancer Res*. 2023 Jan 17;29(2):349-363. doi: 10.1158/1078-0432.CCR-22-1893. Erratum in: *Clin Cancer Res*. 2023 Jan 17;29(2):501. PMID: 36099324; PMCID: PMC9851980.
5. Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCs Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommos FKF, Kruitwagen RFP, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodriguez-

Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Toloczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommos S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. *Cancer*. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582. Epub 2022 Dec 26. PMID: 36572991; PMCID: PMC10107112.

Presentations

1. OncLive – all faculty presented at a well-attended “Update on Gynecologic Oncology” in Charlotte
2. Goodwin HR, Drury LK, Stump H, Lee M, Naumann RW, Crane EK, Puechl A, Lees B, Delara R, Casablanca Y, Brown J. House of cards? Final histology may differ from initial diagnosis in ovarian cancer patients undergoing neoadjuvant chemotherapy (Goodwin HL, presenter; Brown J, mentor). Winter Meeting of the Society of Gynecologic Oncology, February 2023.
3. Delara R, Pal D, Maddeboina K, Naumann RW, Crane E, Brown J, Arditti PM, Dryden HL, Yada B, Sha W, Durden D, McHale C. Treating endometrial adenocarcinoma using multitarget PI3K/BRD4/CD4/6/9 small molecule inhibitors. Poster Presentation (R. Delara presenter). Society of Gynecologic Oncology, Annual Meeting on Women’s Cancer, Tampa, FL, March 2023.
4. Lees B, Morton W, Krotz L, Keating E, Mullan S, Brown J, Crane E, Naumann RW, Puechl A, Davenport S, Hall JB, et al. Universal sexual health screening in gynecologic cancer patients. Poster presentation. Society of Gynecologic Oncology, Annual Meeting on Women’s Cancer, Tampa, FL, March 2023.
5. Duska L, Romano K, Holman L, Crane E, et al. A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer. Oral Plenary, Society of Gynecologic Oncology, Annual Meeting on Women’s Cancer, Tampa, FL, March 2023.
6. Burris B, Lees L, Brown J, Davenport S, et al. Prevalence of clitoral adhesions in patients who have undergone breast cancer care. Poster presentation, ISSWSH, February 2023.
7. Naumann RW. The future of ADC’s. SGO Winter Meeting, GOG Partners Group, Whistler, BC, Canada. January 2023.
8. Naumann RW. Targeted therapy in ovarian cancer. Grand Rounds, Levine Cancer Institute at Atrium Health Wake Forest University Comprehensive Cancer Center, Charlotte, NC. March 2023.
9. Naumann RW. High Intermediate Risk Endometrial Cancer. Educational lecture for fellowship. March 2023.
10. Naumann RW. Recurrent Cervical Cancer. Educational lecture for fellowship. March 2023.
11. Brown J. Debate: Minimally invasive surgery versus open surgery for interval cytoreduction in ovarian cancer. Society of Gynecologic Oncology, Annual Meeting on Women’s Cancer, Tampa, FL, March 2023.
12. Brown J. NRG Podcast Recording, SGO Clinical Trials Subcommittee, February 2023.
13. Brown J. Benign Gynecologists’ Approach to the Adnexal Mass. Webinar for the AAGL, March 2023.
14. Brown J. A focus on the evidence-based aspects of advanced endometrial cancer care. Association of Managed Care Pharmacists, San Antonio, TX, March 2023.

15. Brown J. Featured on “Let’s talk about LGSOC” website

Committee and Leadership Activities at SGO:

Dr. Puechl – SGO Bridges

Dr. Crane – Fellowship Director meeting, CPC – doing a podcast writing paper on TKI toxicity

Dr. Casablanca – Chair of surgical course

Dr. Lees – Quality Committee

Dr. Naumann – Chair of Winter SGO Meeting; Annual Meeting Program Committee 2024

Dr. Brown – Board; Board Liaison to Annual Meeting Program Committee for 2023 and 2024

Awards/Honors/Appointments:

1. Ritchie Delara: Deal Fund Travel Award, Wake Forest Baptist Comprehensive Cancer Center

2. Ritchie Delara: \$20,000 Grant from the Carolinas Ovarian Cancer Fund for her project “Treating PtEN/PI3K co-mutated endometrial adenocarcinoma using novel multitarget PI3K/BRD4/CD4/6/9 small molecule inhibitors” (Mentors D Durden, RW Naumann, J Brown)

3. Ritchie Delara: Young Investigator Award, Wake Forest School of Medicine (\$8000)

4. Top Doctor Awards: Dr. Crane, Dr. Naumann, Dr. Brown

5. E Crane – Core Committee, NRG Oncology Developmental Therapeutics Committee

6. RW Naumann – Board of Directors, Foundation for Women’s Cancers

7. RW Naumann – Co-Chair, PMRC 2, LCI Atrium Health Wake Forest University Comprehensive Cancer Center

8. RW Naumann – Chair of Business Development Committee, GOG Partners Group

9. RW Naumann – Co-Director, IGCS 360 Learning Website, International Gynecologic Cancer Society

10. J. Brown – 2023 Exceptional Women in Medicine Award

11. J. Brown – 2023 Exceptional Women in Oncology Award